Table 1.
Patients’ characteristics
| Patient | Age | Gender | Smoking (Pack‐years) | FEV1/FVC | %FEV1 | GOLD stage | Treatment for COPD | Lobe resected |
|---|---|---|---|---|---|---|---|---|
| Nonsmoker1 | 70 | F | 0 | 78.0 | 122.9 | N.A. | N.A. | RU |
| Nonsmoker2 | 81 | F | 0 | 70.2 | 98.9 | N.A. | N.A. | LU |
| Nonsmoker3 | 78 | F | 0 | 78.9 | 104.2 | N.A. | N.A. | RL |
| Nonsmoker4 | 69 | F | 0 | 84.0 | 94.2 | N.A. | N.A. | RL |
| Smoker1 | 76 | M | 61.5 | 91.8 | 117.0 | N.A. | N.A. | LL |
| Smoker2 | 81 | M | 60 | 82.0 | 92.7 | N.A. | N.A. | LU |
| Smoker3 | 44 | M | 1 | 83.6 | 106.5 | N.A. | N.A. | RU |
| Smoker4 | 62 | M | 60 | 82.0 | 94.0 | N.A. | N.A. | RU |
| COPD1 | 70 | M | 127.5 | 51.3 | 78.0 | A | LAMA | RL |
| COPD2 | 79 | M | 11.5 | 61.2 | 77.8 | A | LABA | LU |
| COPD3 | 51 | M | 30 | 68.1 | 73.3 | A | LAMA | RU |
COPD, chronic obstructive pulmonary disease; FEV1, force expiratory volume in 1 s; FVC, forced vital capacity; %FEV1, percent predicted forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; LAMA, long‐acting muscarinic antagonist; LABA, long‐acting β2 agonist; N.A., not applicable; RU, right upper lobe; LU, left upper lobe; RL right lower lobe; LL, left lower lobe.